On March 21, 2025 Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, reported positive results from the VERIFI clinical validation of its next-generation test for pancreatic cancer on March 19, 2025 (Press release, Immunovia, MAR 21, 2025, View Source [SID1234651350]). As a follow up, Immunovia will host a webcast on Monday, March 24 at 3 pm CET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jeff Borcherding, Immunovia CEO and Norma Alonzo Palma, PhD, VP Clinical and Medical Affairs will present additional study results and share implications of the study.

The webcast will be held in English and will offer attendees the opportunity to ask questions. Here is the link to join the webcast:
View Source

A recording of the presentation will be available on Immunovia’s website following the webcast.